Skip to content
value.today

Trillium Therapeutics Inc.

Formerly Stem Cell Therapeutics Corp., Neurogenesis Biotech Corp.

Total raised
$20 M
1 round on record
Latest round
$20 M
Dec 2017
First round on record
Dec 2017
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Trillium Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2017$20 MNo. 1$10 to $50 million

Trillium Therapeutics Inc.: Raise no. 1, Dec 2017

Investors in this round

2 investors had bought by the notice of Dec 12, 2017: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,198,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Ontario, Canada

People named in the notice

  • Eric Sievers · Executive Officer
  • James Parsons · Executive Officer
  • Niclas Stiernholm · Executive Officer, Director
  • Penka Petrova · Executive Officer
  • Robert Uger · Executive Officer
  • Calvin Stiller · Director
  • Helen Tayton-Martin · Director
  • Henry Frieson · Director
  • Luke Beshar · Director
  • Michael Moore · Director
  • Robert Kirkman · Director
  • Thomas Reynolds · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cowen and Company, LLC (CRD 7616) · New York, New YorkSold in all US states

Remarks in the notice

  • On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees, including executives.”

Signed by James Parsons, Cfo. Newest notice filed Dec 12, 2017. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Trillium Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2017).

    SEC Form D · Dec 2017

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2017

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Trillium Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Trillium Therapeutics Inc.
NameRoleNamed in
Eric SieversExecutive officerDec 2017
James ParsonsExecutive officerDec 2017
Niclas StiernholmExecutive officerDec 2017
Penka PetrovaExecutive officerDec 2017
Robert UgerExecutive officerDec 2017
Calvin StillerDirectorDec 2017
Helen Tayton-MartinDirectorDec 2017
Henry FriesonDirectorDec 2017
Luke BesharDirectorDec 2017
Michael MooreDirectorDec 2017
Niclas StiernholmDirectorDec 2017
Robert KirkmanDirectorDec 2017
Thomas ReynoldsDirectorDec 2017